Compare DNOW & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DNOW | GPCR |
|---|---|---|
| Founded | 1862 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.8B |
| IPO Year | 2014 | 2023 |
| Metric | DNOW | GPCR |
|---|---|---|
| Price | $13.23 | $37.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $16.67 | ★ $103.17 |
| AVG Volume (30 Days) | ★ 3.1M | 754.9K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,648,000,000.00 | N/A |
| Revenue This Year | $69.47 | N/A |
| Revenue Next Year | $8.01 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 25.68 | N/A |
| 52 Week Low | $10.94 | $15.80 |
| 52 Week High | $17.26 | $94.90 |
| Indicator | DNOW | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 56.12 | 32.50 |
| Support Level | $13.05 | $30.82 |
| Resistance Level | $13.96 | $40.29 |
| Average True Range (ATR) | 0.43 | 2.15 |
| MACD | -0.04 | 0.04 |
| Stochastic Oscillator | 48.09 | 14.44 |
Dnow Inc is a provider of energy and industrial solutions and a distributor of pipe, valves, and fittings (PVF) and pumps, as well as fabrication, assembly, and testing of process and production equipment. It provides a broad mix of products required to build and maintain essential infrastructure and operating equipment across upstream, midstream, gas utilities, downstream, energy transition, and industrial markets, along with value-added supply chain solutions and technical product expertise supported by digital offerings through its DigitalNOW and MRCGO e-commerce platforms. The company operates mainly under the DNOW and MRC brands and has three reportable segments: the United States, which generates the majority of revenue, Canada, and International.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.